ivermectin in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
0.40 [0.13 ; 1.23 ] I-TECH (Lim), 2022, Krolewiecki, 2020, Shahbaznejad, 2020 3 0% 608 moderate not evaluable deathsdetailed results Abd-Elsalam, 2021 0.74 [0.16; 3.42]
Galan, 2021 0.94 [0.51; 1.73]
Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
Hashim A, 2020 0.48 [0.11; 1.99]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
Okumuş, 2020 0.58 [0.18; 1.91]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
0.66 [0.44 ; 1.00 ] Abd-Elsalam, 2021, Galan, 2021, Gonzalez (IVER), 2020, Hashim A, 2020, I-TECH (Lim), 2022, Kirti, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, Okumuş, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 10 0% 1,767 moderate critical deaths (time to event analysis only)detailed results Galan, 2021 0.94 [0.51; 1.73]
0.94 [0.51 ; 1.73 ] Galan, 2021 1 0% 168 NA not evaluable clinical deteriorationdetailed results Hashim A, 2020 0.40 [0.10; 1.63]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
0.66 [0.32 ; 1.34 ] Hashim A, 2020, I-TECH (Lim), 2022, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 4 69% 1,118 moderate not evaluable clinical improvementdetailed results Chachar, 2020 1.19 [0.38; 3.72]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Okumuş, 2020 1.51 [0.54; 4.24]
1.67 [1.05 ; 2.66 ] Chachar, 2020, NCT04523831 (Mahmud), 2020, Okumuş, 2020 3 0% 510 moderate not evaluable clinical improvement (7-day)detailed results Chachar, 2020 1.19 [0.38; 3.72]
Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
1.26 [0.68 ; 2.32 ] Chachar, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020 3 82% 525 moderate not evaluable clinical improvement (time to event analysis only)detailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable death or ventilationdetailed results Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
0.89 [0.30 ; 2.64 ] Gonzalez (IVER), 2020 1 0% 73 NA not evaluable hospital dischargedetailed results Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
Kirti, 2021 1.20 [0.73; 1.98]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
1.25 [0.80 ; 1.95 ] Gonzalez (IVER), 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 310 moderate not evaluable mechanical ventilationdetailed results Abd-Elsalam, 2021 1.00 [0.20; 5.11]
Galan, 2021 0.14 [0.03; 0.71]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Shahbaznejad, 2020 2.24 [0.19; 25.88]
0.45 [0.22 ; 0.95 ] Abd-Elsalam, 2021, Galan, 2021, I-TECH (Lim), 2022, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shahbaznejad, 2020 6 0% 1,159 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.93 [0.78 ; 1.10 ] Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 138 low not evaluable viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Bukhari, 2021 0.91 [0.02; 46.94]
3.54 [1.03 ; 12.13 ] Ahmed, 2020, Bukhari, 2021 2 0% 158 serious not evaluable viral clearance by day 7detailed results Bukhari, 2021 11.56 [3.53; 37.91]
Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
1.44 [0.69 ; 3.00 ] Bukhari, 2021, Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 4 83% 336 moderate not evaluable ICU admissiondetailed results Galan, 2021 1.42 [0.68; 2.99]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Kirti, 2021 0.90 [0.30; 2.70]
1.10 [0.64 ; 1.86 ] Galan, 2021, I-TECH (Lim), 2022, Kirti, 2021 3 0% 770 moderate not evaluable serious adverse eventsdetailed results Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
1.49 [0.20 ; 10.91 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 560 moderate not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
1.52 [0.72 ; 3.24 ] Chaccour, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 4 10% 584 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 20:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 684,886
- roots T: 290
